Eluding anaphylaxis allows peptide-specific prevention of the relapsing stage of experimental autoimmune encephalomyelitis

Keith W. Wegmann, H. G. Archie Bouwer, Ruth H. Whitham, David J. Hinrichs

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

We have used a peptide derived from Acanthamoeba castellanii (ACA) to treat the relapsing phase of EAE that develops in SJL mice following immunization with the PLP 139-151 peptide. The native sequence of the ACA 81-95 peptide that shares key residues with the PLP 139-151 peptide is weakly encephalitogenic in SJL mice but is not recognized by antiserum from SJL mice immunized with PLP 139-151. A single amino acid change to the ACA 81-95 peptide sequence significantly enhanced its encephalitogenicity. When administered to SJL mice as a nonlinear peptide octamer, the modified ACA peptide prevented relapsing episodes of EAE in SJL mice previously immunized with the PLP 139-151 encephalitogenic peptide.

Original languageEnglish (US)
Pages (from-to)46-52
Number of pages7
JournalJournal of Neuroimmunology
Volume274
Issue number1-2
DOIs
StatePublished - Jan 1 2014

Keywords

  • Peptide mimic
  • Peptide octamer
  • Prevention of relapsing disease
  • Relapsing EAE

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Eluding anaphylaxis allows peptide-specific prevention of the relapsing stage of experimental autoimmune encephalomyelitis'. Together they form a unique fingerprint.

  • Cite this